Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 1 | Journal of Biomedical Science

Fig. 1

From: USP9X-mediated REV1 deubiquitination promotes lung cancer radioresistance via the action of REV1 as a Rad18 molecular scaffold for cystathionine γ-lyase

Fig. 1

Targeting REV1 enhances lung cancer radiosensitivity in vivo but not in vitroA Control or stable knockdown REV1 A549 lung cancer cells were selected to construct a subcutaneous transplantation tumor model in nude mice, which were then randomly divided into four groups. A total of 10 Gy x 1 F radiation treatment was given to the radiotherapy group after the tumor reached 100 mm3, and the tumor volume was measured every three days. Data are shown as the mean tumor volume ± SEM. **P < 0.01, ***P < 0.001 (n = 8 or 7 mice/group). B Weight of transplanted tumors in mice of each group in panel A. **P < 0.01, ***P < 0.001 (n = 8 or 7/group). C A549 cells were transfected with control or siREV1 for 48 h, digested, and counted. Cells were irradiated with 0, 2, 4, 6, and 8 Gy X-rays after wall attachment, and the number of cell groupings with more than 50 cells were considered colonies and was recorded after 14 days of culture to obtain the cell survival curve. D A549 lung cancer cells were used to generate a subcutaneous transplantation tumor model in nude mice and mice were randomly divided into four groups. JH-RE-06 was used at a final concentration of 1.6 mg/kg, and the drug was administered by intraperitoneal injection twice a week beginning once the tumor volume reached 100 mm3. The experimental group requiring radiotherapy was subjected to 10 Gy of radiotherapy 1 day after drug administration, and tumor volume was measured every three days. Data are shown as the mean tumor volume ± SEM. **P < 0.01 (n = 8 or 7 mice/group). The tumor doubling time (TDT) for Vehicle, JH-RE-06, Vehicle + IR, and JH-RE-06 + IR was 2.82 ± 0.58 days, 4.06 ± 1.13 days, 4.01 ± 0.30 days, and 5.98 ± 2.00 days, respectively. The enhancement factor (EF) of JH-RE-06 was 1.61. E Weight of transplanted tumors in each group of mice in the D graph. ***P < 0.001 (n = 8 or 7/group). F After treatment of A549 cells with different concentrations of JH-RE-06 for 24 h, digestions were counted on spread plates, and cells were irradiated with corresponding doses of X-ray after wall attachment. After 14 days, the number of cell spheres with more than 50 cells was recorded, and cell survival curves were depicted

Back to article page